Pharming Q3 revenue surges 21% to $117.6 million

• Pharming expects third-quarter 2026 revenue of approximately US$117.6 million, up 21% from US$97.3 million a year earlier.
• RUCONEST revenue increased 14% to US$93.8 million, while Joenja sales rose 58% to US$23.8 million, with operating expenses nearly unchanged.
• Pharming narrowed its 2026 revenue outlook to US$380 million–US$390 million and moved its full earnings release forward to October 27.

Pharming Group (NASDAQ:PHAR) expects third-quarter 2026 revenue of approximately US$117.6 million, up 21% year over year, according to preliminary unaudited results.

Revenue increased from US$97.3 million a year earlier, exceeding analyst consensus, while expected operating expenses remained nearly unchanged at US$74.6 million.

RUCONEST generated approximately US$93.8 million, up 14% annually and 30% sequentially, while Joenja revenue increased 58% to US$23.8 million.

Pharming narrowed its 2026 revenue guidance to US$380 million–US$390 million and lowered operating expense expectations to US$310 million–US$315 million.

The company moved its full earnings release to October 27 from November 5, following revenue above and expenses below analyst consensus.

Pharming attributed RUCONEST's quarterly recovery partly to stabilizing US demand and earlier seasonal inventory purchases by a specialty pharmacy customer.

Joenja's growth reflected increased US patient treatment and international demand, including launches in Germany and Japan during the quarter.